**Abstract**

**Background:** Renal impairment is a common feature in multiple myeloma and is considered a poor prognostic factor.

**Aim:** To determine the impact of novel drugs (i.e. bortezomib, lenalidomide and thalidomide) in the treatment of myeloma patients with renal impairment. The primary endpoint was overall survival and secondary endpoints were time to next treatment and response.

**Methods:** The study population included all patients diagnosed with treatment-demanding multiple myeloma January 2000 to June 2011 at 15 Swedish hospitals. Renal impairment was defined as an estimated glomerular filtration rate under 60 mL/min/1.73 m².

**Result:** The study population consisted of 1538 patients, of which 680 had renal impairment at diagnosis. The median overall survival in patients with renal impairment was 33 months, which was significantly shorter than 52 months in patients with normal renal function (P<0.001). Novel agents in first line improved overall survival (median 60 months) in non-high-dose treated patients with renal impairment (n = 143) as compared to those treated with conventional cytotoxic drugs (n = 411) (median 27 months) (P<0.001). In the multivariate analysis up front treatment with bortezomib was an independent factor for better overall survival in non-high-dose treated renally impaired patients. High-dose treated renally impaired patients had significantly better median overall survival than non-high-dose ones (74 versus 26 months) and novel drugs did not significantly improve survival further in these patients. Patients with renal impairment had both a shorter median time to next treatment and a lower response rate than those with normal renal function. However, novel drugs and high dose treatment lead to a significantly longer time to next treatment and the use of novel agents significantly improved the response rate of these patients.

**Conclusion:** High dose treatment and novel drugs, especially bortezomib, can effectively overcome the negative impact of renal impairment in patients with multiple myeloma.

---

**Introduction**

Although the five-year survival for multiple myeloma (MM) patients has gradually increased over the last decades, especially with the use of high-dose chemotherapy and novel agents such as protease inhibitors and immunomodulatory drugs (IMiDs), MM is still considered incurable by conventional means. For the majority of patients the goal of therapy i.e. prolonged survival and preventing progression is related to the quality of response to initial therapy and depth of remissions reached [1,2].

Renal impairment (RI) is a relatively common feature of MM both at diagnosis and in relapsed/refractory MM [3]. With the use of conventional chemotherapy, it has been shown in several studies that renal impairment at diagnosis correlates to inferior survival [4,5], significant morbidity and increased early death rate.
The current gold standard for the treatment of patients less than 65 years of age is high-dose chemotherapy (HDT) followed by autologous stem cell transplantation [6]. However, the use of alkylators during induction treatment is associated with low response rate in patients with MM and RI [7]. Dexamethasone alone or in combination with cyclophosphamide is superior to melphalan containing regimens, because the latter are more dependent on renal elimination [7]. The addition of novel agents such as bortezomib has resulted in a substantial increase in the number of patients responding to therapy when compared to conventional therapy. Bortezomib is a proteasome inhibitor that promotes apoptosis, prevents DNA repair and inhibits proliferation [8] and it is effective in both newly diagnosed MM and relapsed/refractory MM [9]. It can be administered at the full-approved dose and schedule in patients with impaired renal function, because neither the pharmacokinetics nor the primary metabolic pathway of bortezomib are affected by renal impairment [10,11]. Moreover, other novel agents such as the IMiDs lenalidomide and thalidomide increase the susceptibility of tumor cells to lymphocyte-mediated immunosurveillance, which leads to enhanced cytotoxicity towards previously tolerated tumor cells [12,13]. However, lenalidomide is mainly excreted by the kidney [14] while thalidomide pharmacokinetics is not affected by renal function [15]. Currently there are limited data for the efficacy of IMiDs in patients with MM and RI.

The objective of this study is to understand the impact of RI on response to treatment, time to next treatment (TTNT) and most importantly survival in the era of novel agents (i.e. bortezomib, lenalidomide and thalidomide). In this retrospective study, we demonstrate that the use of novel drugs, especially bortezomib can effectively improve response, increase TTNT and enhance overall survival (OS) in multiple myeloma patients with renal impairment.

Materials and Methods

Study population

Consecutive patients diagnosed with MM between January 2000 and June 2011 at 7 university clinics, 5 regional centers and 3 local hospitals in Sweden were included. All patients were identified from the Swedish Cancer Registry, which covers 96.3% of all individuals with malignant disease [16]. Patients were excluded if they had non-treatment demanding disease (watch and wait), plasma cell leukemia or solitary plasmacytoma.

All data were collected from the hospitals’ electronic medical records and, in the case of death, from the national death registry. The study has received ethical approval from the Regional Ethical Vetting Board in Stockholm, Sweden. No informed consent was obtained because this was not required by the ethical committee. The patient information was anonymized and de-identified prior to analysis.

For each patient data regarding age, sex, type of myeloma and extent of bone disease as well as laboratory measurements of calcium, hemoglobin, β2-microglobulin, albumin and creatinine were collected at the time of diagnosis. Serum M-protein and urine M-protein values were collected at baseline and every significant change in the M-protein level was noted. In general, these proteins were measured on a monthly basis or at the start of every treatment cycle. For each treatment line the types of drugs given for MM were noted, with specific start and stop dates for each drug or drug combination. In the case of allogeneic stem cell transplantation the date was recorded and the patient was censored in all analysis after this date.

The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula:

\[
eGFR \text{ in mL/min/1.73 m}^2 = 186.3 \times (S\text{-creatinine/88.4})^{-1.154} \times (\text{age})^{-0.203} \times 0.742 \times \text{female}^{1.209}
\]

Renal function was classified according to National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) chronic kidney disease classification [18] (Table 1). In this study RI was defined as eGFR < 60 mL/min/1.73 m\(^2\).

The study population was divided according to Fig. 1.

To evaluate renal response, all MM patients from our hospital were selected. Patients with a GFR < 30 mL/min were identified and for these patients all serum creatinine values were gathered from diagnosis until death or end of follow-up. The patients were also followed regarding changes in body weight. This cohort was divided into those receiving bortezomib and those receiving other drug combinations (control group). The control group consisted of different treatment regimes: melphalan-based, cyclophosphamide-based, VAD-based (vincristine, adriamycin and prednisone), IMiDs-based and other single drugs or drug combinations.

Definition of endpoints

Near complete response was defined as an undetectable M-protein in the blood and urine by standard electrophoresis but was not always confirmed by immunofixation since it was not required in clinical practice. Very good partial response (VGPR) was defined as at least 90% reduction of M-protein or a decrease to < 200 mg/24 h in the urine M-protein levels. Partial response (PR) was defined as a 50% reduction in M-protein. No response (NR) was defined as less than 50% reduction of M-protein. Progress was considered when M-protein increased by 25% in serum and/or urine, absolute increases of ≥ 5 g/L in serum, or ≥ 200 mg/24 hours in urine [19]. Time to next treatment was defined as the time between the start date of the current treatment line and the start date of the next treatment line, death or last follow-up. OS was calculated from the start of the treatment until death or last follow-up.

Renal response was assessed according to the criteria suggested by Ludwig et al and the International Myeloma Group as either a complete response (CRrenal) defined as an improvement of GFR from < 30 mL/min at baseline to ≥ 60 mL/min; a partial response (PRrenal) defined as an improvement of GFR from < 15 mL/min at baseline to 30–59 mL/min; a minimal response (MRrenal) defined as an improvement of GFR from < 15 mL/min at baseline to 15–29 mL/min or from 15–29 mL/min to 30–59 mL/min or other, when there was no renal response or the response did not reach a MR renal criteria [20,21].

Statistical methods

The Mann-Whitney test for uncorrelated means was performed to investigate possible differences between two independent groups.

| Table 1. Classification of renal function according to National Kidney Foundation Kidney Disease Outcomes Quality Initiative. |
|-----------------------------------------------|
| Stage | Estimated glomerular filtration rate (mL/min/1.73 m\(^2\)) |
|------|-------------------------------------------------|
| 1    | ≥90                                             |
| 2    | 60–89                                           |
| 3    | 30–59                                           |
| 4    | 15–29                                           |
| 5    | <15                                             |

doi:10.1371/journal.pone.0101819.001
groups. In order to evaluate the variables in contingency tables, the Fisher’s Exact Test was performed. Cox regression analyses were used to identify predictive factors and life table curves were calculated according to Kaplan-Meier and compared using log-rank tests. In addition, descriptive statistics were used to characterize the data. A probability value \( P \) of <0.05 was considered as significant.

**Results**

**Patients enrolled in this study**

The patients enrolled in this study were divided according to Fig. 1.

The median age at diagnosis was 73 years and 51% of the patients were male. The most common subtype was IgG (53%) followed by IgA (21%), Bence Jones (21%) and other (3%); 63% of the patients had RI stage 3, 21% stage 4 and 17% stage 5. Population characteristics are shown in (Tables 2–3).

Of the 1538 patients 556 came from our hospital. Of these 95 patients had a GFR, \( 50 \text{ mL/min} \) at diagnosis.

**Overall survival in patients with or without renal impairment**

Patients with RI at diagnosis had a significantly worse median OS than those without RI (Fig. 2A). Further, there was a clear correlation between the degree of RI and OS (Fig. 2B).

In the non-HDT group the existence of renal failure correlated with impaired OS (Fig. 2A). Further, there was a clear correlation between the degree of RI and OS (Fig. 2B).

**Novel agents improved response to treatment among the patients with renal impairment**

Non-RI patients had a higher response rate than the RI patients: 74% reached at least PR after 1st line treatment compared to 65%. However, after using novel agent in the 1st treatment line 85% of the RI patients reached at least PR, which can be compared to 56% for the RI patients treated with conventional agents. Of the bortezomib treated patients 85% reached at least PR after the 1st treatment line (Fig. 5).

**Renal response**

Of the patients treated with bortezomib in 1st line 11 of 12 (92%) improved their GFR \( \geq \text{MR renal} \) compared to 57 of 83
### Table 2. Population characteristics for all patients comparing those with and without renal impairment.

|                          | HDT                  | Non-HDT               |
|--------------------------|----------------------|-----------------------|
|                          | Renal impairment     | Renal impairment      |
|                          | Yes | No | P  | Yes | No | P  |
| **No. of patients**      | 224 | 258 |    | 456 | 600 |    |
| **Mean age**             | 58  | 59  | 0.76 | 76  | 75  | 0.66 |
| **Type of MM, %**        |      |     |     |      |     |     |
| IgG                      | 50.0 | 59.3 |   | 54.8 | 62.8 |   |
| IgA                      | 25.0 | 26.0 |   | 19.3 | 21.8 |   |
| BJ                       | 19.2 | 8.9  |   | 21.9 | 10.2 |   |
| Others                   | 4.9  | 5.0  |   | 2.4  | 4.7  |   |
| Missing                  | 0.9  | 0.8  |   | 1.5  | 0.5  |   |
| **Laboratory values at diagnosis, mean** |        |     |     |      |     |     |
| Albumin, g/L             | 32 | 34 | 0.006 | 33 | 34 | 0.005 |
| Hb, g/L                  | 100 | 114,2 | <0.001 | 102 | 114 | <0.001 |
| Ca, mmol/L               | 2.6 | 2.4 | <0.001 | 2.6 | 2.4 | <0.001 |
| β2m, mg/L                | 9.5 | 3.3 | <0.001 | 8.1 | 3.3 | <0.001 |
| **Stage of renal function, %** |     |     |     |     |
| 1                        | 0 | 34.6 | 0 | 31.3 |
| 2                        | 0 | 65.4 | 0 | 66.7 |
| 3                        | 57.8 | 0 | 65.1 | 0 |
| 4                        | 22.9 | 0 | 18.9 | 0 |
| 5                        | 19.3 | 0 | 16.0 | 0 |
| **Novel drugs, %**       |      |     |     |      |     |     |
| Yes                      | 25.6 | 36.2 | 30.5 | 28.0 |
| No                       | 74.4 | 63.8 | 69.5 | 72.0 |

The HDT patients are those that at some point have received high-dose treatment, irrespective of treatment line and the non-HDT those that have not. Patients classified has having received novel drugs implies that they have received this treatment in one or more treatment lines.

HDT, high-dose treated; non-HDT, non-high-dose treated; MM, multiple myeloma; novel drugs, bortezomib, lenalidomide or thalidomide; IgG, immunoglobulin G; IgA, immunoglobulin A; BJ, Bence Jones; Hb, hemoglobin; Ca, calcium; β2m, beta-2-mikroglobulin.

doi:10.1371/journal.pone.0101819.t002
**Table 3.** Population characteristics for patients with renal impairment treated with novel agents.

|                          | HDT with renal impairment | Non-HDT with renal impairment |
|--------------------------|---------------------------|-----------------------------|
|                          | Novel treatment           | Novel treatment             |
|                          | Yes | No | P  | Yes | No | P  |
| No. of patients          | 57  | 166| 0.62 | 135 | 308|     |
| Mean age                 | 59  | 58 | 0.62 | 75  | 75 | 0.67 |
| Type of MM, %            |     |    |     |     |    |     |
| IgG                      | 49.1| 50 |      | 53.3| 55.8|     |
| IgA                      | 31.6| 22.9| 0.62 | 17.8| 19.8|     |
| BJ                       | 15.8| 20.5| 0.67 | 25.2| 20.5|     |
| Other                    | 3.5 | 5.4 |      | 2.2 | 2.3 |     |
| Missing                  | 0   | 1.2 |      | 1.5 | 1.6 |     |
| Laboratory values, mean  |     |    |     |     |    |     |
| Albumin, g/L             | 30  | 33 | 0.03 | 33  | 32 | 0.76 |
| Hb, g/L                  | 98  | 100| 0.46 | 102 | 101| 0.70 |
| Ca, mmol/L               | 2.5 | 2.6| 0.34 | 2.6 | 2.6| 0.24 |
| B2M, mg/L                | 10.2| 9.2| 0.72 | 8.3 | 8.0| 0.78 |
| Creatinine               | 314 | 238| 0.04 | 295 | 217| 0.002|
| Stage of renal function, %|   |    |     |     |    |     |
| 3                        | 52.6| 59.6|     | 60  | 67.2|     |
| 4                        | 21.1| 23.5|     | 18.5| 19.2|     |
| 5                        | 26.3| 16.9|     | 21.5| 13.6|     |

The HDT patients are those that at some point have received high-dose treatment, irrespective of treatment line, and the non-HDT those that have not. Patients classified have received novel drugs implies that they have received this treatment in one or more treatment lines.

HDT, high-dose treated; non-HDT, non-high-dose treated; MM, multiple myeloma; IgG, immunoglobulin G; IgA, immunoglobulin A; BJ, Bence Jones; Hb, hemoglobin; Ca, calcium; B2M, beta-2-mikroglobulin. doi:10.1371/journal.pone.0101819.t003
patients (69%) in the control group ($P=0.049$). Four of the 12 (33%) bortezomib treated patients and 38 of 83 patients (46%) in the control group reached CRrenal after 1st treatment line.

Novel agents and HDT prolonged time to next treatment
RI implied a shorter median TTNT after 1st line (13 versus 20 months, $P<0.001$). However, TTNT between 2nd and 3rd treatment lines was not affected by renal function at diagnosis, neither among the HDT-patients nor among the non-HDT-patients (Fig. 6A–B).

Additionally, the non-HDT patients with RI had a median TTNT after 1st line of 11 months, compared to 14.5 months for patients without RI ($P<0.001$). Novel drugs prolonged the TTNT after 1st line in these patients (Fig. 6C) and bortezomib treatment lead to a significant improvement of TTNT after adjusting for age, calcium, hemoglobin and albumin ($P=0.02$) (Fig. 6D).

On the contrary, the HDT population with RI had a median TTNT after 1st line of 30 months compared to patients without RI who had a median TTNT of 35 months ($P=0.159$) and novel agents in 1st line did not affect median TTNT in this population (Fig. 6E).

Discussion
Our main finding is that novel agents, especially bortezomib, are associated with survival benefits in MM patients with RI in a real life setting. By using novel agents the OS among RI patients not eligible for HDT was significantly improved from a median 21 to 60 months. Bortezomib-based regimens also improved the median OS to 60 months and was an independent factor to enhance OS in non-HDT patients with RI ($P=0.02$). Moreover, the difference in survival between those with and without RI vanished with the use of novel agents. The median TTNT between the 1st and 2nd treatment lines in non-HDT patients with RI was more than doubled by the use of novel agents. However, the same effect on TTNT was not seen in the HDT group.

Renal impairment is a frequent complication of MM and has been associated with poor outcome. The present study investigated the impact of RI on survival and myeloma response in a large cohort of MM patients treated in a real life setting; all consecutive cases were obtained from the Swedish Cancer Registry. The data in this study derive from several different hospitals, not only referral centers. Therefore, we believe that our population

Figure 2. Overall survival in symptomatic multiple myeloma patients. (A) Patients presenting with renal impairment compared to those with normal renal function. (B) Patients divided into five groups according to the chronic kidney disease classification.
doi:10.1371/journal.pone.0101819.g002

Figure 3. Overall survival for non-high-dose treated (non-HDT) patients with renal impairment. (A) Patients treated with novel agents (bortezomb, thalidomide or lenalidomide) compared to conventional agents in the 1st treatment line. (B) Patients treated with bortezomib compared to conventional agents in the 1st treatment line.
doi:10.1371/journal.pone.0101819.g003
represents the full spectrum of different MM patients and we consider the study representative for the whole Swedish MM population.

One reason for the improved OS in RI patients with novel agents is a better disease control [22]. We found a clear improvement of responses when using novel agents compared to the use of conventional agents. In line with the study by Dimopoulos et al [23] we have observed that among RI patients treated with novel agents in the 1st treatment line 85% obtained more than PR. This was significantly better than for those treated with conventional drugs (66%). Interestingly, more than half of the patients with RI treated with bortezomib-based regimens reached at least VGPR (55%) even though the amount of patients reaching at least PR was the same (85%).

We found that renal response occurred more frequently in patients treated with bortezomib compared to conventional agents and this result corresponds with earlier studies [24,25]. Renal response is correlated to improved myeloma response [25] and improved OS [26]. When renal response coincides with myeloma response the outcome is improved compared to when renal
response and myeloma response occur separately [26]. However, renal response can also occur in patients not experiencing a myeloma response [24,25].

Since this is a retrospective study with data from 15 different hospitals it is influenced by center specific clinical routines. This includes measurement of response, which was mostly done...

Figure 6. Time to next treatment in patients with and without renal impairment at diagnosis. (A) In high-dose treated (HDT) patients with and without renal impairment after 2nd line of therapy. (B) In non-HDT patients with and without renal impairment after 2nd line of therapy. (C) Non-HDT patients with renal impairment treated with novel agents (bortezomib, lenalidomide or thalidomide) in the 1st line compared to those treated with conventional agents (Conv.). (D) Non-HDT patients with renal impairment treated with bortezomib (Bz) in the 1st line compared to those treated with conventional agents. (E) HDT patients with renal impairment treated with novel agents (bortezomib, lenalidomide or thalidomide) in the 1st line compared to those treated with conventional agents.

doi:10.1371/journal.pone.0101819.g006
Novel Drugs Overcome the Negative Impact of Renal Failure in MM

monthly but sometimes every 6–8 weeks. These variations might affect time to progression and progression-free survival. However, treatments were started when the physician considered the relapse to be treatment demanding and this is why we consider data on TTNT to be more reliable than time to progression and progression-free survival. Since it is more likely that patients treated at university clinics could be included in clinical trials than those treated at local hospitals, it is also impossible to avoid some degree of selection bias in the choice of treatment. One weakness of this study is the lack of information about concomitant diseases, thus making it impossible to correct for comorbidity. However, the results were stratified according to age, sex, type of MM and severity of RI at diagnosis have been unchanged during the last 20 years the survival among these patients has improved significantly since the introduction of novel agents in 2000. The survival has improved even more after 2005 when the use of bortezomib increased. This indicates an advantage of bortezomib-based therapy, even though the correlation could not be verified [22]. A study analyzing the effect of novel agents on newly diagnosed MM patients with RI found that RI was not independently associated with inferior survival [27]. An earlier study of MM patients presenting with RI (the majority of which had received earlier MM treatment) observed an overall response rate of 80% in previously untreated patients and 58% in relapsed/refractory patients after bortezomib treatment [28].

In conclusion, the use of novel agents such as IMiDs and most importantly bortezomib, improves OS in MM patients with RI leading to the same median OS regardless the existence of RI. We therefore conclude that novel agents can overcome the negative impact of RI and improve the outcome of MM treatment.

Supporting Information

Table S1 Univariate analysis of factors affecting overall survival in multiple myeloma patients with renal impairment. Both HDT and non-HDT patients are included. (DOCX)

Table S2 Multivariate analysis of factors affecting overall survival in non-HDT patients treated with bortezomib in 1st treatment line. (DOCX)

Author Contributions

Conceived and designed the experiments: KU HN. Analyzed the data: EA HN. Contributed reagents/materials/analysis tools: KU J. Lund. Contributed to the writing of the manuscript: KU AD J. Lund J. Living GG EH JA EA HN.

References

1. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 2612–2624.
2. Dingh D, Pacheco JM, Nowakowski GS, Kumar SK, Dispensieri A, et al. (2007) Relationship between depth of response and outcome in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25: 4933–4937.
3. Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of internal medicine 150: 1693–1695.
4. Abbot KC, Agodoa LY (2001) Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clinical nephrology 56: 207–210.
5. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J (1991) Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. The Quarterly journal of medicine 79: 517–525.
6. Harousseau JL, Saugy M, Jir J, Richardson P (2004) Multiple myeloma. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program: 237–256.
7. Dimopoulos MA, Kaunitz E, Resnich L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1463–1493.
8. Laubach J, Richardson P (2011) Hematology. Bortezomib and dexamethasone induction for multiple myeloma. Nature reviews Clinical oncology 8: 8–10.
9. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28: 4976–4984.
10. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, et al. (2005) Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug metabolism and disposition: the biological fate of chemicals 33: 771–777.
11. Uyttenshuy V, Lu C, Miwa G, Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug metabolism and disposition: the biological fate of chemicals 33: 1723–1728.
12. Chang DH, Liu N, Klinec V, Hassoun H, Mazumder A, et al. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618–621.
13. Wu L, Adams M, Carter T, Chen R, Muller G, et al. (2006) Lenalidomide enhances the natural killer cell and monocye-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 12: 4560–4567.
14. Chen N, Lai H, Kong L, Kumar G, Zeldis JB, et al. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47: 1466–1475.
15. Eriksson T, Hoglund P, Turcson I, Waage A, Don BR, et al. (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55: 1701–1706.
16. Barlow L, Westergren K, Holmgren I, Tallback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48: 27–33.
17. Levey AS, Bosch JP, Lewis JB, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine 130: 461–470.
18. (2002) Part 4. Definition and classification of stages of chronic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 39: S6–S75.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British journal of haematology 102: 1115–1123.
20. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28: 4976–4984.
21. Ludwig H, Adam Z, Hajek R, Grel R, Tholova E, et al. (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28: 4635–4641.
22. Dimopoulos MA, Delimpasi S, Katsodritou E, Vassou A, Kyrtsonis MC, et al. (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25: 195–200.
23. Dimopoulos MA, Rossouw M, Giotzamanouds M, Nikitas N, Pimouros E, et al. (2013) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27: 425–429.
24. Dimopoulos MA, Richardson PG, Schlag R, Khnagava NK, Shipberg O, et al. (2009) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately
impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27: 6086–6093.

25. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, et al. (2010) Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34: 1393–1397.

26. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, et al. (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 9: 302–306.

27. Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, et al. (2011) Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia & lymphoma 52: 2299–2303.

28. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, et al. (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clinical lymphoma & myeloma 9: 302–306.